Skip to main content
European Commission logo print header

Macrophage aging and rejuvenation

Cel

Tissue resident macrophages are essentially present in every organ of the body and perform critical functions in immunity,
tissue homeostasis and regeneration. Recent evidence shows that resident macrophages can originate from embryonic
progenitors and be maintained in tissues long term by local proliferation independently of monocytes. This self-renewal
ability, however, appears to decline with age, with potentially major consequences for the response to infection, the
resolution of inflammation and the ability for tissue regeneration. Understanding the decline of self-renewal in the aging
macrophage may thus hold key elements for maintaining healthy tissue integrity. Drawing from analogies to stem cell self-renewal we want to decipher the molecular and cellular parameters of macrophage self-renewal and its decline with age.
We want to understand the age-associated changes in gene expression and epigenetic identity of tissue macrophage
populations with the ultimate goal to reverse age dependent decline in self-renewal and function. Results from my
laboratory have identified transcription factors that control the access to a network of self-renewal genes that are also used in stem cells. Using several complementary genetic mouse models tapping into this network we want to investigate whether its activation in resident macrophage population in vivo can rejuvenate their self-renewal capacity and revert aging related changes. These approaches will be complemented by unbiased genome wide screens in vivo using latest generation CRISPR/Cas9 genome editing technology to identify new signaling pathways guiding macrophage self-renewal and aging. Using innovate combinations of genetics and adoptive transfer protocols we will test whether this knowledge can be employed to reverse macrophage dependent loss of immune competence and failed tissue regeneration with age. Our results will lead to new general insight and potential novel cellular therapies for degenerative diseases.

System finansowania

ERC-ADG - Advanced Grant

Instytucja przyjmująca

TECHNISCHE UNIVERSITAET DRESDEN
Wkład UE netto
€ 1 352 846,78
Adres
HELMHOLTZSTRASSE 10
01069 Dresden
Niemcy

Zobacz na mapie

Region
Sachsen Dresden Dresden, Kreisfreie Stadt
Rodzaj działalności
Higher or Secondary Education Establishments
Linki
Koszt całkowity
€ 1 352 846,78

Beneficjenci (2)